THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
- Funded by Biomedical Advanced Research and Development Authority (BARDA)
- Total publications:5 publications
Grant number: 75A50121C00077
Grant search
Key facts
Disease
Ebola, Marburg virus diseaseStart & end year
20212027Known Financial Commitments (USD)
$95,592,504Funder
Biomedical Advanced Research and Development Authority (BARDA)Research Location
United States of AmericaLead Research Institution
INTERNATIONAL AIDS VACCINE INITIATIVE INC.Research Priority Alignment
N/A
Research Category
Vaccines research, development and implementationResearch Subcategory
Pre-clinical studiesSpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
5 Publications linked via Europe PMC
Last Updated:5 days ago
View all publications at Europe PMC